China Heparin Industry Report, 2010-2011
  • Sep./2011
  • Hard Copy
  • USD $1,900
  • Pages:71
  • Single User License
    (PDF Unprintable)       
  • USD $1,800
  • Code: HM006
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,700
  • Hard Copy + Single User License
  • USD $2,100
      
With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the world. In 2010, there were 24 heparin API manufacturers with the heparin sodium API production license granted by SFDA in China, with the export volume of heparin API reaching 15.9 trillion units, with the market share making up 52.1% of the world's total in the corresponding period.

Export Volume and Proportion in the World of Heparin API in China, 2007-2010 (trillion units)
201109035.gif 
Source: ResearchInChina

Europe and America are the major export destinations of heparin API made in China. From January to July of 2011, heparin and heparinate made in China were exported to 44 countries. In terms of export volume, the top 5 export destinations were France, Germany, America, Austria and Italy, with the combined export volume standing at 83.7%.

It is required to obtain CEP certification of EU or FDA authentication of the US for companies to access into the European and American markets. Due to the stringent authentication criterion, many unqualified enterprises are forced to withdraw from the market. As of August, 2011, China had 5 CEP certified heparin API producers and 2 FDA certified ones. In particular, both Shenzhen Hepalink Pharmaceutical     and Changzhou Qianhong Bio-Pharma obtained the two certifications, an edge over the oppositions.

Although it is a large producer of heparin API, the production of downstream unfractionated heparin (UFH) sodium preparations and low-molecular-weight (LMW) heparin preparations in China is still in its infancy.

In the UFH preparation market, 26 Chinese companies have obtained the heparin sodium injection drug production licenses granted by SFDA. Due to the mounting pressure arising from the soaring price of heparin API, there are less than 10 companies that seem competitive in Chinese market, such as Tianjin Biochemical Pharmaceutical, Wanbang Biopharmaceuticals and Shanghai No.1 Chemical & Pharmaceutical, but all of them need to procure upstream raw material for production.

Restricted by the technology, the LMW heparin preparation market of China is dominated by foreign brands. In 2009, Chinese markets of LMW heparin sodium and LMW heparin calcium were dominated by France-based Sanofi’s Clexane and GSK’s Fraxiparine, topping the market with the respective share of 54.5% and 59.0%. However, the LMW heparin preparation products made by domestic companies become increasingly competitive with the enhanced strength in R&D and technology. For instance, the sales of Hebei Changshan Biochemical Pharmaceutical, a company producing LMW heparin calcium injection, rose 72.6% YoY to RMB51.612 million in 2010.
1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2. International Operating Environment of Heparin Industry
2.1 Demand of Heparin Medicine
2.2 Distribution of Heparin Medicine Demand
2.3 Heparin API Demand
2.4 Overseas Competitors
2.5 Related Policies
2.6 Market Forecast

3. Current Development of China Heparin API Industry
3.1 Market Overview
3.2 Demand & Supply
3.3 Competition
3.4 Dynamics
3.5 Related Policies
3.6 Market Forecast

4. Current Development of China Heparin Preparation Industry
4.1 Overview of Antithrombotic Drugs
4.2 Market Overview
4.3 UFH Preparations
4.3.1 International Environment
4.3.2 Market Size
4.3.3 Competition
4.4 LMW Heparin Preparations
4.4.1 International Environment
4.4.2 Market Size
4.5 Demand & Supply
4.6 Competition
4.7 Dynamics & Patents
4.8 Market Forecast
5. Import & Export
5.1 Export
5.1.1 Export Volume
5.1.2 Export Destinations
5.2 Import
5.2.1 Import Destinations
5.2.2 Import Origins

6. Heparin Manufacturers in China
6.1 Shenzhen Hepalink Pharmaceutical
6.1.1 Profile
6.1.2 Operation
6.1.3 Dynamics
6.2 Changzhou Qianhong Bio-Pharma Co., Ltd
6.2.1 Profile
6.2.2 Operation
6.2.3 Dynamics
6.3 Tianjin Chase Sun Pharmaceutical
6.3.1 Profile
6.3.2 Operation
6.3.3 Dynamics
6.4 Hebei Changshan Biochemical Pharmaceutical
6.4.1 Profile
6.4.2 Operation
6.4.3 Dynamics
6.5 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
6.5.1 Profile
6.5.2 Operation
6.6 Yantai Dongcheng Biochemicals Co., Ltd
6.6.1 Profile
6.6.2 Operation
6.7 Wanbang Biopharmaceuticals
6.7.1 Profile
6.7.2 Operation
6.7.3 Dynamics
Application of Heparin Preparations
Heparin Industry Chain
Sales of Heparin Drugs Worldwide, 2003-2012E 
Distribution of Heparin Drug Consumption Worldwide, 2010
Market Size and Growth Rate of Heparin API Worldwide,2007-2013
Forecast of Global Heparin Drug Market Development 
Export Volume and The Global Proportion of Heparin API in China, 2007-2010
Number of Slaughtered Fattened Hogs (Head) and Year-end Number of Hogs (Head) of China, 2003-2010
Price Trend of Crude Sodium Heparin API in China, 2008-2010
Top ten Pharmaceutical Companies by Export Value of Heparin in China, Jan.-Sep.2010
Gross Margin of Major Heparin API Manufacturers in China, 2008-2010
Heparin Sodium API Supply in China and the World and China’s Share, 2011-2013
China Antithrombotic Drug Market Size, 2003-2012
Market Share of China's Major Varieties of Anti-thrombosis Drug in Hospital,2005-2009
Market Size of Heparin Drug in China,2007-2013
Chinese Market Share of Heparin Preparation Products, 2009
Market Size of Global UFH Preparations,2006-2012
Sales of UFH Preparations in China,2006-2012
Market Demand for Heparin Sodium Injection Solution in China, 2007-2012
Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China
Operation of Major UFH Preparations Manufacturers in China,2008-2009
Performance Comparison between Low Molecular Weight Heparin Preparations and UFH Preparations
Market Size of Global Low Molecular Weight Heparin Preparations,2006-2012
Market Size of Low Molecular Weight Heparin Preparations in China,2006-2010
Proportion of Low-molecular Heparin Calcium and Low-molecular Heparin Sodium in Anticoagulant Medicines of China, 2005-2011
Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations
Competition Pattern of China Low-Molecular-Weight Heparin Sodium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Sodium in China, 2009
Competition Pattern of China Low-Molecular-Weight Heparin Calcium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Calcium in China, 2009
Main Patents for LMW Heparin
China LMW Heparin Drug Market Size, 2010-2014 
Export of Key Western Medicines of China, Jan.-Jul. 2011
Export Value and Its Growth Rate of Heparin and Its Salts in China,2008-2011
China’s Export Volume and Price Trend of Heparin Products, 2008-2011
Overseas Market Distribution of Heparin Products in China, Jan.-Jul.2011
Main Chinese Exporting Enterprises of Heparin API and Their Percentages by Export Value, Jan.-Sep., 2009 and Jan.-Sep., 2010
Import Volume and Unit Price Trend of Heparin Products in China, 2008-Jan-Jul.2011
Destinations of China’s Heparin Product Imports, 2008- Jan-Jul.2011 
Import Origins of China Heparin Products, 2008- Jan-Jul.2011 
Heparin Sodium API Operating Revenue and YOY of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007- H1 2011 
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Product Grade, 2007- H1 2011
Gross Margin of Heparin API (by Product) of Shenzhen Hepalink Pharmaceutical Co., Ltd., H12007-2011
Operating Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd. by Region, 2007- H12011
Total Profit and YPY of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007- H12011 
Operating Revenue and Net Income of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007- H1 2011
Operating Revenue (by Product) of Changzhou Qianhong Bio-Pharma Co., Ltd., 2008- H1 2011
Gross Margin (by Product) of Changzhou Qianhong Bio-Pharma Co., Ltd., 2009- H1 2011
Operating Revenue of Changzhou Qianhong Bio-Pharma Co., Ltd. by Region,2007- H1 2011
Top Five Clients of Heparin Sodium API of Changzhou Qianhong Bio-Pharma Co., Ltd, 2009-2010
R&D Input and Its Ratio to Operating Revenue of Changzhou Qianhong Bio-Pharma Co., Ltd, 2008-2010
Operating Revenue and Net Income of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007- H1 2011
Operating Revenue (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2009 - H1 2011
Gross Margin (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2008- H1 2011
Heparin Calcium Operating Revenue and YoY Growth of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2007- H1 2011 
Operating Revenue of Tianjin Chase Sun Pharmaceutical Co., Ltd. by Region, 2008-2011H1 Competition and Distribution of Major Businesses of Tianjin Chase Sun Pharmaceutical Co., Ltd.
Operating Revenue and Net Income of Hebei Changshan Biochemical Pharmaceutical Co., Ltd, 2008-2010 
Operating Revenue (by Product) of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd., 2008-2010
Gross Margin (by Product) of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd., 2008-2010
Operating Revenue of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. by Region, 2008-2010
Sales of Top Five Customers of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. and Their Proportion to total Operating Revenue,2008-2010
R&D Input and Its Ratio to Operating Revenue of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.,2008-2010
Projects under R&D and Expected Target of Changshan Biochemical Pharmaceutical Co., Ltd.
Raising Project of Changshan Biochemical Pharmaceutical Co.,Ltd.
Heparin API Export of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., 2009-2010 (Jan.-Sep. )
Operation of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, 2008-2009 
Operation of Yantai Dongcheng Biochemicals Co., Ltd, 2008-2009 
Heparin API Export of Yantai Dongcheng Biochemicals Co., Ltd, 2009-2010 (Jan.-Sep. )
Operation of Wanbang Biopharmaceuticals, 2008-2009 

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统